336 related articles for article (PubMed ID: 16140924)
1. The proto-oncogene ERG in megakaryoblastic leukemias.
Rainis L; Toki T; Pimanda JE; Rosenthal E; Machol K; Strehl S; Göttgens B; Ito E; Izraeli S
Cancer Res; 2005 Sep; 65(17):7596-602. PubMed ID: 16140924
[TBL] [Abstract][Full Text] [Related]
2. Early lineage priming by trisomy of Erg leads to myeloproliferation in a Down syndrome model.
Ng AP; Hu Y; Metcalf D; Hyland CD; Ierino H; Phipson B; Wu D; Baldwin TM; Kauppi M; Kiu H; Di Rago L; Hilton DJ; Smyth GK; Alexander WS
PLoS Genet; 2015 May; 11(5):e1005211. PubMed ID: 25973911
[TBL] [Abstract][Full Text] [Related]
3. Transposon mutagenesis reveals cooperation of ETS family transcription factors with signaling pathways in erythro-megakaryocytic leukemia.
Tang JZ; Carmichael CL; Shi W; Metcalf D; Ng AP; Hyland CD; Jenkins NA; Copeland NG; Howell VM; Zhao ZJ; Smyth GK; Kile BT; Alexander WS
Proc Natl Acad Sci U S A; 2013 Apr; 110(15):6091-6. PubMed ID: 23533276
[TBL] [Abstract][Full Text] [Related]
4. The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy.
Ge Y; LaFiura KM; Dombkowski AA; Chen Q; Payton SG; Buck SA; Salagrama S; Diakiw AE; Matherly LH; Taub JW
Leukemia; 2008 Mar; 22(3):521-9. PubMed ID: 18094719
[TBL] [Abstract][Full Text] [Related]
5. Forced FOG1 expression in erythroleukemia cells: Induction of erythroid genes and repression of myelo-lymphoid transcription factor PU.1.
Fujiwara T; Sasaki K; Saito K; Hatta S; Ichikawa S; Kobayashi M; Okitsu Y; Fukuhara N; Onishi Y; Harigae H
Biochem Biophys Res Commun; 2017 Apr; 485(2):380-387. PubMed ID: 28216155
[TBL] [Abstract][Full Text] [Related]
6. Hematopoietic overexpression of the transcription factor Erg induces lymphoid and erythro-megakaryocytic leukemia.
Carmichael CL; Metcalf D; Henley KJ; Kruse EA; Di Rago L; Mifsud S; Alexander WS; Kile BT
Proc Natl Acad Sci U S A; 2012 Sep; 109(38):15437-42. PubMed ID: 22936051
[TBL] [Abstract][Full Text] [Related]
7. Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: Amplification discloses overexpression of APP, ETS2, and ERG genes.
Baldus CD; Liyanarachchi S; Mrózek K; Auer H; Tanner SM; Guimond M; Ruppert AS; Mohamed N; Davuluri RV; Caligiuri MA; Bloomfield CD; de la Chapelle A
Proc Natl Acad Sci U S A; 2004 Mar; 101(11):3915-20. PubMed ID: 15007164
[TBL] [Abstract][Full Text] [Related]
8. ERG is a megakaryocytic oncogene.
Salek-Ardakani S; Smooha G; de Boer J; Sebire NJ; Morrow M; Rainis L; Lee S; Williams O; Izraeli S; Brady HJ
Cancer Res; 2009 Jun; 69(11):4665-73. PubMed ID: 19487285
[TBL] [Abstract][Full Text] [Related]
9. Increased dosage of the RUNX1/AML1 gene: a third mode of RUNX leukemia?
Osato M; Ito Y
Crit Rev Eukaryot Gene Expr; 2005; 15(3):217-28. PubMed ID: 16390318
[TBL] [Abstract][Full Text] [Related]
10. ETS2 and ERG promote megakaryopoiesis and synergize with alterations in GATA-1 to immortalize hematopoietic progenitor cells.
Stankiewicz MJ; Crispino JD
Blood; 2009 Apr; 113(14):3337-47. PubMed ID: 19168790
[TBL] [Abstract][Full Text] [Related]
11. Contribution of GATA1 dysfunction to multi-step leukemogenesis.
Shimizu R; Yamamoto M
Cancer Sci; 2012 Dec; 103(12):2039-44. PubMed ID: 22937757
[TBL] [Abstract][Full Text] [Related]
12. miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia.
Klusmann JH; Li Z; Böhmer K; Maroz A; Koch ML; Emmrich S; Godinho FJ; Orkin SH; Reinhardt D
Genes Dev; 2010 Mar; 24(5):478-90. PubMed ID: 20194440
[TBL] [Abstract][Full Text] [Related]
13. Expression of erythroid-specific genes in megakaryoblastic disorders.
Ito E; Kasai M; Toki T; Arai K; Yokoyama M
Leuk Lymphoma; 1996 Nov; 23(5-6):545-50. PubMed ID: 9031085
[TBL] [Abstract][Full Text] [Related]
14. The oncofusion protein FUS-ERG targets key hematopoietic regulators and modulates the all-trans retinoic acid signaling pathway in t(16;21) acute myeloid leukemia.
Sotoca AM; Prange KH; Reijnders B; Mandoli A; Nguyen LN; Stunnenberg HG; Martens JH
Oncogene; 2016 Apr; 35(15):1965-76. PubMed ID: 26148230
[TBL] [Abstract][Full Text] [Related]
15. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome.
Wechsler J; Greene M; McDevitt MA; Anastasi J; Karp JE; Le Beau MM; Crispino JD
Nat Genet; 2002 Sep; 32(1):148-52. PubMed ID: 12172547
[TBL] [Abstract][Full Text] [Related]
16. Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.
Greene ME; Mundschau G; Wechsler J; McDevitt M; Gamis A; Karp J; Gurbuxani S; Arceci R; Crispino JD
Blood Cells Mol Dis; 2003; 31(3):351-6. PubMed ID: 14636651
[TBL] [Abstract][Full Text] [Related]
17. Activity of a heptad of transcription factors is associated with stem cell programs and clinical outcome in acute myeloid leukemia.
Diffner E; Beck D; Gudgin E; Thoms JA; Knezevic K; Pridans C; Foster S; Goode D; Lim WK; Boelen L; Metzeler KH; Micklem G; Bohlander SK; Buske C; Burnett A; Ottersbach K; Vassiliou GS; Olivier J; Wong JW; Göttgens B; Huntly BJ; Pimanda JE
Blood; 2013 Mar; 121(12):2289-300. PubMed ID: 23327922
[TBL] [Abstract][Full Text] [Related]
18. GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder.
Carpenter E; Valverde-Garduno V; Sternberg A; Mitchell C; Roberts I; Vyas P; Vora A
Br J Haematol; 2005 Feb; 128(4):548-51. PubMed ID: 15686466
[TBL] [Abstract][Full Text] [Related]
19. Increased dosage of Runx1/AML1 acts as a positive modulator of myeloid leukemogenesis in BXH2 mice.
Yanagida M; Osato M; Yamashita N; Liqun H; Jacob B; Wu F; Cao X; Nakamura T; Yokomizo T; Takahashi S; Yamamoto M; Shigesada K; Ito Y
Oncogene; 2005 Jun; 24(28):4477-85. PubMed ID: 15856017
[TBL] [Abstract][Full Text] [Related]
20. Transcription of the SCL gene in erythroid and CD34 positive primitive myeloid cells is controlled by a complex network of lineage-restricted chromatin-dependent and chromatin-independent regulatory elements.
Göttgens B; McLaughlin F; Bockamp EO; Fordham JL; Begley CG; Kosmopoulos K; Elefanty AG; Green AR
Oncogene; 1997 Nov; 15(20):2419-28. PubMed ID: 9395238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
